Bone Marrow Transplantation - Pipeline Review, H1 2016

  • ID: 3691103
  • Drug Pipelines
  • 76 pages
  • Global Markets Direct
1 of 5

FEATURED COMPANIES

  • Anchor Therapeutics, Inc.
  • Cleveland BioLabs, Inc.
  • Compugen Ltd.
  • Mesoblast Limited
  • Targazyme, Inc.
  • MORE
Bone Marrow Transplantation - Pipeline Review, H1 2016

Summary

‘Bone Marrow Transplantation - Pipeline Review, H1 2016’, provides an overview of the Bone Marrow Transplantation pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Bone Marrow Transplantation, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Bone Marrow Transplantation and features dormant and discontinued projects.

The report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Bone Marrow Transplantation
- The report reviews pipeline therapeutics for Bone Marrow Transplantation by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Bone Marrow Transplantation therapeutics and enlists all their major and minor projects
- The report assesses Bone Marrow Transplantation therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Bone Marrow Transplantation

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Bone Marrow Transplantation
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Bone Marrow Transplantation pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • Anchor Therapeutics, Inc.
  • Cleveland BioLabs, Inc.
  • Compugen Ltd.
  • Mesoblast Limited
  • Targazyme, Inc.
  • MORE
List of Tables

List of Figures

Introduction

Report Coverage

Bone Marrow Transplantation Overview

Therapeutics Development

Pipeline Products for Bone Marrow Transplantation - Overview

Pipeline Products for Bone Marrow Transplantation - Comparative Analysis

Bone Marrow Transplantation - Therapeutics under Development by Companies

Bone Marrow Transplantation - Therapeutics under Investigation by Universities/Institutes

Bone Marrow Transplantation - Pipeline Products Glance

Late Stage Products

Clinical Stage Products

Early Stage Products

Bone Marrow Transplantation - Products under Development by Companies

Bone Marrow Transplantation - Products under Investigation by Universities/Institutes

Bone Marrow Transplantation - Companies Involved in Therapeutics Development

Anchor Therapeutics, Inc.

Boryung Pharmaceutical Co., Ltd.

Cleveland BioLabs, Inc.

Compugen Ltd.

Mesoblast Limited

Pluristem Therapeutics Inc.

Taiga Biotechnologies, Inc.

Targazyme, Inc.

Bone Marrow Transplantation - Therapeutics Assessment

Assessment by Monotherapy Products

Assessment by Combination Products

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Drug Profiles

(filgrastim + plerixafor) - Drug Profile

Product Description

Mechanism of Action

R&D Progress

ATI-2341 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

BR-05001 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

CBLB-612 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

Cellular Immunotherapy for Bone Marrow Transplantation - Drug Profile

Product Description

Mechanism of Action

R&D Progress

CGEN-15001 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

MPC-CBE - Drug Profile

Product Description

Mechanism of Action

R&D Progress

PLXR-18 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

Protein for Bone Marrow Transplantation - Drug Profile

Product Description

Mechanism of Action

R&D Progress

Small Molecules to Inhibit Perforin for Bone Marrow Transplantation - Drug Profile

Product Description

Mechanism of Action

R&D Progress

TZ-101 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

Bone Marrow Transplantation - Recent Pipeline Updates

Bone Marrow Transplantation - Dormant Projects

Bone Marrow Transplantation - Discontinued Products

Bone Marrow Transplantation - Product Development Milestones

Featured News & Press Releases

Jan 12, 2016: Pluristem Receives U.S. FDA Clearance to Initiate Clinical Trial of PLX-R18 to Treat Insufficient Hematopoietic Recovery Following Bone Marrow Transplant

Nov 17, 2015: Pluristem to Present New Data on PLX-R18 at American Society of Hematology’s Annual Meeting

May 06, 2015: Pluristem Granted European Patent for Use of Cells to Help Treat Damaged Bone Marrow

Mar 24, 2015: Pluristem Announces Key Strategic Objectives for Development of PLX-R18 in Hematopoietic Indications

Mar 03, 2015: Pluristem and Hadassah Medical Center Announce Significant Data Showing PLX-R18 Cells Improve Bone Marrow Transplantation

Dec 04, 2014: Pluristem and Hadassah Medical Center Will Collaborate to Study Potential of PLX-RAD Cells to Improve Bone Marrow and Umbilical Cord Blood Transplant Outcomes

Nov 13, 2014: Cell Source's Megadose Drug Combination Receives Regulatory Approval in Italy to Commence Human Clinical Trials

Oct 27, 2014: Case Western Reserve University to Study Pluristem’s PLX-RAD Cells in Umbilical Cord Blood Transplants for the Treatment of Blood Cancers and Genetic Diseases

May 07, 2013: Pluristem Develops PLX-RAD Cells For Use In Hematology

Sep 05, 2012: Pluristem Therapeutics Announces Successfully Treatment Of Third Critically Ill Patient With PLX Cells Under Compassionate Use

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

Number of Products under Development for Bone Marrow Transplantation, H1 2016

Number of Products under Development for Bone Marrow Transplantation - Comparative Analysis, H1 2016

Number of Products under Development by Companies, H1 2016

Number of Products under Investigation by Universities/Institutes, H1 2016

Comparative Analysis by Late Stage Development, H1 2016

Comparative Analysis by Clinical Stage Development, H1 2016

Comparative Analysis by Early Stage Development, H1 2016

Products under Development by Companies, H1 2016

Products under Investigation by Universities/Institutes, H1 2016

Bone Marrow Transplantation - Pipeline by Anchor Therapeutics, Inc., H1 2016

Bone Marrow Transplantation - Pipeline by Boryung Pharmaceutical Co., Ltd., H1 2016

Bone Marrow Transplantation - Pipeline by Cleveland BioLabs, Inc., H1 2016

Bone Marrow Transplantation - Pipeline by Compugen Ltd., H1 2016

Bone Marrow Transplantation - Pipeline by Mesoblast Limited, H1 2016

Bone Marrow Transplantation - Pipeline by Pluristem Therapeutics Inc., H1 2016

Bone Marrow Transplantation - Pipeline by Taiga Biotechnologies, Inc., H1 2016

Bone Marrow Transplantation - Pipeline by Targazyme, Inc., H1 2016

Assessment by Monotherapy Products, H1 2016

Assessment by Combination Products, H1 2016

Number of Products by Stage and Target, H1 2016

Number of Products by Stage and Mechanism of Action, H1 2016

Number of Products by Stage and Route of Administration, H1 2016

Number of Products by Stage and Molecule Type, H1 2016

Bone Marrow Transplantation Therapeutics - Recent Pipeline Updates, H1 2016

Bone Marrow Transplantation - Dormant Projects, H1 2016

Bone Marrow Transplantation - Discontinued Products, H1 2016

List of Figures

Number of Products under Development for Bone Marrow Transplantation, H1 2016

Number of Products under Development for Bone Marrow Transplantation - Comparative Analysis, H1 2016

Number of Products under Development by Companies, H1 2016

Comparative Analysis by Clinical Stage Development, H1 2016

Comparative Analysis by Early Stage Products, H1 2016

Assessment by Monotherapy Products, H1 2016

Number of Products by Targets, H1 2016

Number of Products by Stage and Targets, H1 2016

Number of Products by Mechanism of Actions, H1 2016

Number of Products by Stage and Mechanism of Actions, H1 2016

Number of Products by Routes of Administration, H1 2016

Number of Products by Stage and Routes of Administration, H1 2016

Number of Products by Molecule Types, H1 2016

Number of Products by Stage and Molecule Types, H1 2016
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
Anchor Therapeutics, Inc.
Boryung Pharmaceutical Co., Ltd.
Cleveland BioLabs, Inc.
Compugen Ltd.
Mesoblast Limited
Pluristem Therapeutics Inc.
Taiga Biotechnologies, Inc.
Targazyme, Inc.
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll